Item 7.01. Regulation FD Disclosure.

Beginning on January 13, 2020, representatives of Turning Point Therapeutics, Inc. (the "Company") will be providing presentation materials (the "Presentation") to certain interested parties. A copy of the Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 8.01 Other Events.

On January 13, 2020, the Company issued a press release providing program updates, including announcing that the U.S. Food and Drug Administration has granted Fast Track designation to the Company's lead drug candidate repotrectinib for the treatment of ROS1-positive advanced non-small cell lung cancer patients who have been previously treated with one prior line of platinum-based chemotherapy and one prior line of a ROS1 tyrosine kinase inhibitor. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K under Item 7.01 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
Number       Description

99.1           Presentation Materials of Turning Point Therapeutics, Inc.

99.2           Press Release issued by Turning Point Therapeutics, Inc. on
             January 13, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses